Meningiomas, the most prevalent form of primary intracranial tumor, have long been a focus of neurosurgical and oncological treatment due to their intracranial location and diverse clinical behavior. Traditionally, the management of these tumors has been guided by histopathological grading as determined by the World Health Organization (WHO), which stratifies meningiomas into grades based on cellular atypia, mitotic activity, and other malignant features. However, this classical histological approach, while foundational, is increasingly challenged by emerging molecular profiling techniques that promise to refine prognostic accuracy and tailor therapeutic strategies to individual patients’ tumor biology.
The advancement in molecular diagnostics has ushered in an era where meningioma classification transcends morphology alone. Genomic and epigenomic analyses have revealed distinct molecular subgroups of meningiomas, profoundly impacting clinical decision-making. These molecular classifiers capture tumor heterogeneity more precisely than conventional methods, allowing for improved prediction of recurrence risk and responsiveness to therapy. Consequently, the integration of molecular profiling into routine clinical practice is rapidly evolving, heralding a paradigm shift where personalized medicine is becoming a tangible reality in meningioma care.
Imaging technology also plays a pivotal role in this evolving landscape. The advent of somatostatin receptor-targeted positron emission tomography combined with computed tomography (PET–CT) or magnetic resonance imaging (MRI) represents a significant leap forward in meningioma detection and delineation. These advanced imaging modalities leverage the overexpression of somatostatin receptors on meningioma cells to enhance visualization of tumor margins, facilitating earlier identification of residual or recurrent disease. This precision in imaging not only aids in diagnostic accuracy but also enables neurosurgeons and radiation oncologists to more effectively plan and deliver localized treatments with minimal collateral damage to healthy brain tissue.
Surgical management of meningiomas remains a cornerstone of treatment, yet the approach has evolved with technological improvements and minimally invasive techniques. Endoscopic surgery and other novel minimally invasive procedures have become increasingly common, permitting safer tumor resections with reduced morbidity. These techniques extend the possibility of complete tumor removal even in anatomically challenging locations, potentially reducing the likelihood of recurrence and minimizing postoperative complications. The continual refinement of surgical methods reflects an overarching trend toward enhancing patient outcomes through less invasive but equally effective interventions.
Radiotherapy continues to be integral in the management of meningiomas, especially for patients with incompletely resected tumors or those not amenable to surgery. Advances in stereotactic radiotherapy platforms have allowed for highly precise delivery of radiation doses targeted at the tumor while sparing adjacent neural structures. This precision reduces treatment-related toxicity and improves local control rates. Moreover, hypofractionated and single-dose radiosurgery approaches offer alternative strategies tailored to the tumor size and location, expanding the therapeutic arsenal available to clinicians.
Another promising frontier in meningioma treatment lies in the realm of systemic therapies. Traditionally, systemic chemotherapy has had limited efficacy in meningiomas; however, recent developments in targeted agents, immune checkpoint inhibitors, and targeted radioligands are changing the therapeutic landscape. Molecular targets identified through genomic studies provide opportunities for precision-targeted therapies that disrupt the signaling pathways critical for tumor growth and survival. Similarly, immunotherapies leverage the patient’s immune system to combat tumor cells, addressing the need for more effective systemic options, particularly in recurrent or higher-grade meningiomas refractory to conventional treatment.
Despite these advances, numerous challenges persist, foremost among them the lack of standardized classification systems that incorporate molecular data alongside histopathology. The heterogeneity in diagnostic criteria complicates the consolidation of clinical trial data and the generalization of findings to routine practice. This underscores the urgent need for international consensus on integrated diagnostic frameworks that combine histological, molecular, and radiographic parameters to optimize patient stratification and treatment selections.
The development of predictive biomarkers remains another critical unmet need. Reliable biomarkers that can forecast tumor behavior, treatment responsiveness, and patient prognosis would enable a truly personalized approach to meningioma management. Current research is focused on identifying molecular signatures and imaging markers that can serve this purpose, but translation to clinical practice is still in progress. The discovery and validation of such biomarkers are essential to move beyond the “one-size-fits-all” treatment paradigm toward bespoke therapeutic regimens for meningioma patients.
Equally important is the optimization of clinical trial design tailored to meningiomas. Given their generally indolent nature and the considerable clinical variability among patients, designing trials that meaningfully assess novel interventions is inherently complex. Innovative trial designs that incorporate biomarker-driven patient selection and adaptive elements may accelerate the evaluation of emerging treatments and better capture clinically relevant endpoints beyond traditional measures such as overall survival.
The multidisciplinary nature of meningioma care is more salient than ever. Optimal management involves a coordinated approach integrating neurosurgeons, radiation oncologists, neuro-oncologists, radiologists, pathologists, and supportive care specialists. This team-based strategy ensures comprehensive evaluation of each case, balancing tumor biology, patient-specific factors, and treatment goals to devise the most appropriate individualized care plan. Multidisciplinary tumor boards and collaborative decision-making forums are becoming the standard of care, facilitating the integration of novel diagnostic and therapeutic modalities into clinical workflows.
The clinical impact of these technological and scientific advances in meningioma management cannot be overstated. Patients now have access to improved diagnostic precision, less invasive surgical options, targeted radiotherapy, and emerging systemic treatments, all of which contribute to enhanced quality of life and prolonged survival. Furthermore, earlier detection of recurrent disease through advanced imaging techniques enables timely interventions, potentially preventing neurological deterioration and reducing the burden of disease progression.
Looking forward, ongoing research and clinical trials continue to explore promising avenues in meningioma treatment. Novel immunotherapeutic agents targeting immune evasion mechanisms, innovative radioligand therapies, and next-generation targeted molecular inhibitors are under intensive investigation. The integration of artificial intelligence and machine learning algorithms into imaging and molecular data analysis holds promise for further refining diagnosis and predicting therapeutic responses, driving forward the frontier of precision oncology in meningiomas.
As the scientific community converges on these multidisciplinary innovations, the vision of truly personalized meningioma care becomes increasingly attainable. This integrated roadmap, combining histopathological rigor with molecular insight and advanced imaging, provides a framework not only for current patient management but also for guiding future research priorities. Such coordinated efforts are essential to surmount existing challenges and to usher in a new era where treatment strategies are precisely matched to tumor biology and patient needs.
The culmination of these efforts will redefine the care paradigm for meningiomas. By harnessing the synergy of surgical advancements, precision radiotherapy, molecularly targeted systemic therapies, and sophisticated diagnostic tools, clinicians are progressively steering away from generic treatment algorithms toward personalized pathways that optimize clinical outcomes. This transformation embodies the essence of precision oncology, marking a definitive leap forward in the management of meningiomas and exemplifying the broader shift in neuro-oncology.
In summary, meningioma management today stands at an exciting crossroads fueled by technological progress and molecular medicine. The integration of comprehensive diagnostic classification, innovative imaging modalities, refined surgical techniques, advanced radiotherapy, and promising systemic therapies collectively enhances clinical care. Although challenges remain in uniform classification, biomarker discovery, and trial design, the ongoing multidisciplinary collaboration and scientific innovation hold tremendous promise. These developments signal a future where meningioma treatment is not only more effective but also distinctly personalized, ultimately improving patient prognosis and quality of life.
Subject of Research: Multidisciplinary management approaches in meningiomas, incorporating molecular classification, advanced imaging, surgery, radiotherapy, and systemic therapies.
Article Title: Multidisciplinary management of meningiomas in the era of precision oncology.
Article References:
Assadi, M., Juweid, M.E., Lohmann, P. et al. Multidisciplinary management of meningiomas in the era of precision oncology. Nat Rev Clin Oncol (2026). https://doi.org/10.1038/s41571-026-01148-9
Image Credits: AI Generated
Tags: advanced imaging in meningioma diagnosisepigenomic analysis in neuro-oncologygenomic classification of brain tumorsmolecular profiling of meningiomasmultidisciplinary meningioma carepersonalized medicine for intracranial tumorsprecision oncology in meningioma treatmentprognostic biomarkers in brain tumorssomatostatin receptor PET-CT imagingtargeted therapies for meningiomastumor heterogeneity in meningiomasWHO histopathological grading meningiomas
